Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

227.79 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Apr 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗

April 27, 2026

This pharma stock is cheap for a reason.

Via The Motley Fool

Topics Intellectual Property

Small Cap or Megacap: Which Healthcare Stock Is Right for You? ↗

April 22, 2026

Healthcare companies with different market caps offer different rewards and challenges.

Via The Motley Fool

Top gainers and losers in the S&P500 index during Wednesday's after-hours session. ↗

April 22, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

Founders Capital Loads Up on Midstream Stock With $3.4 Million Buy, According to Recent SEC Filing ↗

April 22, 2026

Plains GP Holdings runs a major North American network for crude oil and NGL transport and storage, serving producers and refiners.

Via The Motley Fool

Topics Energy Regulatory Compliance

3 Giant Dividend Stocks Raising Payouts With Yields Up to 4% ↗

April 20, 2026

Johnson & Johnson, Albertsons, and Procter & Gamble have each raised their dividends, lifting yields to between 2.3% and 4% despite mixed performance in 2025.

Via MarketBeat

Could This Healthcare Stock Help Make You Rich Over the Next Decade? ↗

April 19, 2026

Intuitive Surgical has already made many of its early investors wealthy.

Via The Motley Fool

Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report? ↗

April 18, 2026

Solid results weren't impressive enough to move the stock price higher.

Via The Motley Fool

Topics Intellectual Property

3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗

April 18, 2026

This once-beaten-down pharma stock remains an intriguing turnaround story.

Via The Motley Fool

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗

April 16, 2026

These companies boast significant upside potential.

Via The Motley Fool

This "Boring" Dividend King Is Quietly Turning Into a Growth Machine ↗

April 16, 2026

The blue chip dividend stock is quietly growing again as a streamlined company.

Via The Motley Fool

3 Healthcare Stocks That Have Held Up in Every Market Downturn ↗

April 16, 2026

Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.

Via The Motley Fool

Topics Economy

Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now ↗

April 16, 2026

Three Dividend Aristocrats offer yields above the 10-year Treasury while delivering income growth and potential capital appreciation

Via MarketBeat

Topics Bonds Earnings Economy

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson ↗

April 16, 2026

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Via Benzinga

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

These Analysts Boost Their Forecasts On Johnson & Johnson Following Strong Q1 Results ↗

April 15, 2026

Johnson & Johnson (NYSE:JNJ) reports upbeat earnings for Q1, with higher sales and raised fiscal 2026 guidance. Some analysts raise price targets.

Via Benzinga

Johnson & Johnson Posts Solid Q1 To Kickstart 'Year Of Accelerating Growth,' Says Bullish Analyst ↗

April 15, 2026

Johnson & Johnson reports strong Q1, beating expectations and setting the stage for future growth. Analysts maintain Buy rating.

Via Benzinga

Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A

April 15, 2026

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately...

Via MarketMinute

Topics Economy

Transcript: Johnson & Johnson Q1 2026 Earnings Conference Call ↗

April 15, 2026

Via Benzinga

Oil Drops, Dimon Warns, and the Record Is Within Reach ↗

April 15, 2026

Within 0.2% of its January all-time high. That's where the S&P 500 closed on Tuesday, not quite there yet, but close enough that the question investors are asking has quietly shifted from "when does...

Via Chartmill

Topics Artificial Intelligence Economy Government

MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat

April 14, 2026

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...

Via MarketMinute

Topics Bankruptcy Earnings Economy

What Makes a Healthcare Stock Worth Holding Through a Recession? ↗

April 14, 2026

Not all healthcare stocks are defensive in a downturn. Here's what to consider.

Via The Motley Fool

Topics Economy

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results ↗

April 14, 2026

Via MarketBeat

Johnson & Johnson Q1 2026 Earnings Call Transcript ↗

April 14, 2026

Johnson & Johnson (NASDAQ: JNJ) reported first-quarter financial results on Tuesday. The transcript from the company's first-quarter earnings call has been provided below.

Via Benzinga

Topics Earnings

Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone

April 14, 2026

NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across...

Via MarketMinute

Topics Economy Intellectual Property

Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend ↗

April 14, 2026

Johnson & Johnson Q1 pharma growth offsets immunology decline; company raises guidance and extends dividend streak.

Via Benzinga

The New J&J: A 2026 Deep Dive into the Global Healthcare Titan

April 14, 2026

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,...

Via Finterra

Topics Artificial Intelligence Death Economy

Dow Jones' J&J Slips Despite Beating First-Quarter Calls, Hiking Guidance ↗

April 14, 2026

Johnson & Johnson stock fell early Tuesday despite better-than-expected first-quarter sales and earnings, and a guidance hike.

Via Investor's Business Daily

Topics Stocks

Dow Jones Stocks In Spotlight: JPMorgan, Johnson & Johnson Among This Week's Earnings Reports ↗

April 13, 2026

Four of the 30 Dow Jones Industrial Average stocks report this week. Here's a look at the companies and what the key figures to watch are.

Via Benzinga

Topics Stocks

Is This Dividend King With a 63-Year Dividend Streak A Buy Before April 14?

April 13, 2026

This Dividend King offers a rare mix of safety and upside heading into earnings.

Via Barchart.com

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.